HIV: treating Pneumocystis pneumonia (PCP)

摘要: Introduction Pneumocystis pneumonia (PCP) is a common AIDS-defining opportunistic illness in people with HIV infection, but its incidence has fallen use of prophylactic treatment. Without treatment, PCP likely to be fatal AIDS, so placebo-controlled studies would considered unethical. Methods and outcomes We conducted systematic review aimed answer the following clinical questions: What are effects first-line antipneumocystis treatments for infected HIV? adjuvant corticosteroids receiving who have not responded treatment? searched: Medline, Embase, The Cochrane Library, other important databases up May 2008 (BMJ Clinical Evidence reviews updated periodically, please check our website most up-to-date version this review). included harms alerts from relevant organisations such as US Food Drug Administration (FDA) UK Medicines Healthcare products Regulatory Agency (MHRA). Results found 22 reviews, RCTs, or observational that met inclusion criteria. performed GRADE evaluation quality evidence interventions. Conclusions In we present information relating effectiveness safety interventions: corticosteroids, aerosolised intravenous pentamidine, atovaquone, clindamycin-primaquone, treatment after failure trimethoprim-dapsone, trimethoprim-sulfamethoxazole (TMP-SMX, co-trimoxazole).